TIM
ZVRA icon

Thompson Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Thompson Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$7 – 533
2024
Q3 		$7 Hold
1
– – ﹤0.01% 497
2024
Q2 		$5 Hold
1
– – ﹤0.01% 497
2024
Q1 		$6 Hold
1
– – ﹤0.01% 514
2023
Q4 		$7 Buy
+1
New +$5 ﹤0.01% 427

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Investment Management's ZVRA Position: Q4 2024 in Review

Thompson Investment Management sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 1 share — an estimated $7 sold.

Thompson Investment Management first reported a position in ZVRA in Q4 2023 and held it in 4 quarters. The position peaked at $7 in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

  • Thompson Investment Management reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Thompson Investment Management sold 1 Zevra Therapeutics share in Q4 2024, an estimated $7.
  • Thompson Investment Management first reported a position in Zevra Therapeutics in Q4 2023 and held it in 4 quarters.
  • Thompson Investment Management's Zevra Therapeutics position peaked at $7 in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Thompson Investment Management's 13F filing for Q4 2024, filed 28 Jan 2025.